Multiple Sclerosis Disease Activity After Discontinuing Natalizumab for Pregnancy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
JAMA Netw Open 2022 Jan 04;5(1)e2144750, K Hellwig, M Tokic, S Thiel, N Esters, C Spicher, N Timmesfeld, AI Ciplea, R Gold, A Langer-GouldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.